ClinicalTrials.gg
Active, not recruitingNCT05771480TOURMALINEUpdated Jul 29, 2026

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

A Phase 3 interventional study of Durvalumab and Gemcitabine monotherapy in Biliary Tract Cancer, sponsored by AstraZeneca. Active, not recruiting at 34 sites in 8 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
142
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing durvalumab in Biliary Tract Neoplasms — 5 open to participants now, 11 under way, 2 of them phase 3. durvalumab · Biliary Tract Neoplasms.

Enrollment
4th of 16
142 · median 50
Started
2023
with 3 others
Phase 3
3 of 16
none open now
Primary completion
2025-10
later than 5 of 10 live
Registered
10th of 16
by date
Lead sponsor
4 of 16
AstraZeneca

Among the 16 studies testing durvalumab in Biliary Tract Neoplasms, this one is the 4th largest by enrollment, is one of 4 that started in 2023, is one of 3 in phase 3, reaches primary completion later than 5 of the 10 other live ones, and was the 10th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

5 of the 16 studies testing durvalumab in Biliary Tract Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing durvalumab in Biliary Tract Neoplasms, or all of them as a file.
02

Study summary

A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.

Read the detailed description

This study involves assessing the safety and efficacy of durvalumab in combination with different gemcitabine-based chemotherapy regimens as first line therapy for aBTC. The target population of interest in this study is participants with aBTC who are ≥ 18 years of age and above legal age per local regulations with WHO/ECOG PS of 0 to 2 at enrolment and who are not eligible for locoregional therapy. Participants with WHO/ECOG PS 2 will be capped at 20% of the overall treated participant population.

The study consists of 4 periods: screening period (Day-28 to Day -1), treatment period up to 8 cycles of gemcitabine-based chemotherapy regimens with durvalumab, maintenance treatment with durvalumab alone or in combination with gemcitabine-based chemotherapy (with the exception of paclitaxel), and then safety and survival follow-up.

03

Conditions studied

  • Biliary Tract Cancer

Keywords

  • monoclonal antibodies
  • PD-L1 antagonist
  • Durvalumab
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, unresectable advanced or biliary tract carcinoma (BTC) including cholangiocarcinoma (intrahepatic or extrahepatic), gallbladder carcinoma, and ampulla of Vater (AoV) carcinoma
  • Participants with unresectable or metastatic BTC
  • A World Health Organisation Performance Status (WHO/ECOG PS) of 0 to 2
  • At least one lesion that qualifies as a version 1.1 (RECIST 1.1) target lesion at baseline
  • Adequate organ and bone marrow function
  • Body weight of > 30 kg
  • Negative pregnancy test (serum) for women of
  • Female participants must be one year (amenorrhoeic for 12 months without an alternative medical cause)
  • Male and female participants and their partners must be surgically sterile or on their chosen method of as per the protocol.

Exclusion criteria

Exclusion Criteria:

  • Any evidence of diseases such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diseases, active infection, active interstitial lung disease/pneumonitis, serious chronic gastrointestinal conditions associated with diarrhoea, psychiatric illness/social situations, history of uncontrolled or symptomatic cardiac disease, and history of allogenic organ transplant
  • Active or prior documented or inflammatory disorders
  • History of another primary , except for malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of study intervention
  • History of
  • History of active primary immunodeficiency
  • Known to have tested positive for [HIV] (positive HIV 1/2 antibodies) or active tuberculosis infection
  • Participants co-infected with virus (HBV) and virus (HCV) or co-infected with HBV and Hepatitis D virus (HDV)
  • Persistent toxicities ( [CTCAE] Grade > 1) caused by previous anticancer therapy
  • Central nervous system requiring treatment or history of spinal cord compression
  • Known allergy or to any of the study intervention or any of the study intervention .
  • Any concurrent chemotherapy, other than the one allowed in the study, medicinal product (IMP), biologic, or hormonal therapy for cancer treatment
  • Palliative radiotherapy with a limited field of radiation within 2 weeks of the first dose of study intervention, or radiotherapy with a wide field of radiation or radiotherapy affecting more than 30% of the bone marrow within 4 weeks before the first dose of study intervention
  • Receipt of within 30 days prior to the first dose of study intervention
  • Major surgical procedure within 28 days prior to the first dose of IMP
  • Prior exposure to immune-mediated therapy excluding therapeutic anticancer vaccines
  • Receipt of the last dose of anticancer therapy within 28 days prior to the first dose of IMP
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Durvalumab + Gemcitabine based chemotherapy

    Participants will receive durvalumab 1500mg every 3 or 4 weeks, in combination with continuation of all or some of the original background gemcitabine based chemotherapy every 3 or 2 weeks for up to a maximum of 8 cycles of chemotherapy. Durvalumab 1500mg is given as a 60-minute IV infusion in the first cycle (Day 1) and as a 30-minute IV infusion in following cycles. Upon completing 8 cycles of background gemcitabine-chemotherapy, or after discontinuing any of the combination chemotherapies due to toxicity before completing 8 cycles, participants are eligible to continue receiving durvalumab 1500 mg IV every 4 weeks either alone or in combination with gemcitabine-based chemotherapy (with the exception of paclitaxel), as per investigator's discretion.

    Biological: Durvalumab · Drug: Gemcitabine monotherapy · Drug: Gemcitabine + cisplatin · Drug: Gemcitabine + oxaliplatin · Drug: Gemcitabine + carboplatin · Drug: Gemcitabine + cisplatin + S-1 · Drug: Gemcitabine + S-1 · Drug: Gemcitabine + cisplatin + albumin-bound paclitaxel

Interventions

  • BiologicalDurvalumab

    Participants will receive 1500 mg every 3 weeks, or every 4 weeks (in combination with chemotherapy every 3 weeks, or every 2 weeks, respectively) from cycle 1 to cycle 8 of chemotherapy. Upon completion, participants will receive 1500 mg every 4 weeks (as monotherapy)

    Also known as: Background Gemcitabine-based Chemotherapy Regimen

  • DrugGemcitabine monotherapy

    Gemcitabine monotherapy as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)

    Also known as: Background Gemcitabine-based Chemotherapy Regimen

  • DrugGemcitabine + cisplatin

    Drug pages: Gemcitabine · Cisplatin

    Gemcitabine plus cisplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab) for WHO/ECOG PS 2 participants only

    Also known as: Background Gemcitabine-based Chemotherapy Regimen

  • DrugGemcitabine + oxaliplatin

    Drug pages: Gemcitabine · Oxaliplatin

    Gemcitabine + oxaliplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)

    Also known as: Background Gemcitabine-based Chemotherapy Regimen

  • DrugGemcitabine + carboplatin

    Drug pages: Gemcitabine · Carboplatin

    Gemcitabine + carboplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)

    Also known as: Background Gemcitabine-based Chemotherapy Regimen

  • DrugGemcitabine + cisplatin + S-1

    Drug pages: Gemcitabine · Cisplatin · Tegafur · Gimeracil · Oxonic Acid

    Gemcitabine + cisplatin + S-1 as background gemcitabine-based chemotherapy every 2 weeks (i.e, 4 cycles of durvalumab)

    Also known as: Background Gemcitabine-based Chemotherapy Regimen., This regimen is not allowed for countries in the European Union.

  • DrugGemcitabine + S-1

    Drug pages: Gemcitabine · Tegafur · Gimeracil · Oxonic Acid

    Gemcitabine + S-1 as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)

    Also known as: Background Gemcitabine-based Chemotherapy Regimen, This regimen is not allowed for countries in the European Union.

  • DrugGemcitabine + cisplatin + albumin-bound paclitaxel

    Drug pages: Gemcitabine · Cisplatin · Albumin-Bound Paclitaxel

    Gemcitabine + cisplatin + albumin-bound paclitaxel as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)

    Also known as: Background gemcitabine-based chemotherapy Regimen, This regimen is not allowed for countries in the European Union.

06

What researchers measure

Primary outcomes

  1. Number of participants with Grade 3 or 4 possibly related adverse event (PRAE)

    PRAE is defined as an AE which has been assessed by the investigator to be possibly related to IMP.

    Time frame: Within 6 months after the initiation of Investigational Medicinal Product (IMP)

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of the first dose of IMP until death due to any cause.

    Time frame: From the date of the first dose of IMP until death due to any cause [approx. upto 33 months]

  2. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, as determined by the investigator at local site per RECIST 1.1.

    Time frame: From the date of first dose of IMP until progression, or the last evaluable assessment in the absence of progression [assessed up to 33 months]

  3. Progression-Free Survival (PFS)

    PFS is defined as the time from the first dose of IMP until the date of disease progression (PD) or death due to any cause.

    Time frame: From the date of the first dose of IMP until until the date of objective PD or death [approx. up to 33 months]

  4. Disease Control Rate (DCR)

    DCR is defined as the % of participants who have a best objective response of complete response or partial response (by week 24 or 32), or who have stable disease for 24 or 32 weeks.

    Time frame: Week 24 and Week 32

  5. Duration of Response (DOR)

    DOR is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression.

    Time frame: From the date of first documented response until the first date of documented progression or death in the absence of disease progression [approx. up to 33 months]

  6. Duration of Treatment (DOT)

    DOT is defined as time on study intervention.

    Time frame: From date of start of IMP, until 27 days after last dose of IMP or date of death [approx. up to 33 months]

  7. Number of participants with AEs, including PRAEs, adverse events of special interest (AESIs), immune-mediated adverse events (imAEs) and serious adverse events (SAEs)

    To assess the safety and tolerability profile of durvalumab combined with background gemcitabine-based chemotherapy

    Time frame: From the date of first dose of IMP until long-term follow-up i.e. until 90 days following discontinuation of the last dose of IMP [approx. up to 33 months]

  8. Number of participants with IRRs and hypersensitivity/anaphylactic reactions

    To assess the safety and tolerability profile of durvalumab combined with background gemcitabine-based chemotherapy

    Time frame: From the date of first dose of IMP until 90 days following discontinuation of the last dose of IMP [approx. up to 33 months]

  9. European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire (EORTC QLQ C-30)

    To assess disease and treatment related symptoms and HRQoL. EORTC QLQ-C30 consists of 30 items and measures symptoms, functioning, and global health status/QoL for all cancer types. Questions are grouped into 5 multi-item functional scales (physical, role, emotional, cognitive, and social), 3 multi-item symptom scales (fatigue, pain, and nausea/vomiting), a 2-item global QoL scale, 5 single items assessing additional symptoms commonly reported by cancer participants (dyspnoea, loss of appetite, insomnia, constipation, and diarrhoea), and one item on the financial impact of the disease. The EORTC QLQ-C30 is a valid and reliable PRO instrument in this participant population

    Time frame: From date of first dose of IMP, until the date of the first clinically meaningful deterioration [approx. up to 33 months]

  10. EORTC QLQ-BIL21 Score

    To assess disease- and treatment related symptoms and HRQoL. The EORTC QLQ-BIL21 is a disease-specific (cholangiocarcinoma and cancer of the gallbladder) questionnaire. It consists of 21 items including one question each for side effects, equipment issues, and weight loss, as well as 5 scales (eating symptoms, jaundice symptoms, tiredness, pain, and anxiety). A higher score indicates greater difficulties. The EORTC QLQ-BIL21 is a valid and reliable PRO instrument in this participant population.

    Time frame: From date of first dose of IMP, until the date of the first clinically meaningful deterioration [approx. up to 33 months]

07

Study locations

34 sites
  • Research Site
    Mobile, Alabama 36607, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Clichy, 92110, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Montpellier, 34090, France
  • Research Site
    Villejuif, 94800, France
  • Research Site
    Chemnitz, 09131, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Castelfranco Veneto, 31033, Italy
  • Research Site
    Foggia, 71122, Italy
  • Research Site
    Palermo, 90146, Italy
  • Research Site
    Pisa, 56126, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Kanazawa, 920-8641, Japan
  • Research Site
    Kashiwa, 227-8577, Japan
  • Research Site
    Kyoto, 606-8507, Japan
  • Research Site
    Osaka, 541-8567, Japan
  • Research Site
    Sendai, 980-8574, Japan
  • Research Site
    Ube, 755-8505, Japan
  • Research Site
    Wakayama, 641-8509, Japan
  • Research Site
    Yokohama, 241-8515, Japan
  • Research Site
    Singapore, 169610, Singapore
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Madrid, 28027, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Seville, 41013, Spain
08

References and documents

Publications

  • Oh DY, Ikeda M, Macarulla T, He AR, Park JO, Kitano M, Giordano G, Kim KP, Wirth T, Tai D, Bouattour M, Pressiani T, Dayyani F, Lamarca A, Emeribe U, Radke S, Sun P, Baur B, Vogel A. Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study. J Hepatol. 2026 Jul 6:S0168-8278(26)02658-9. doi: 10.1016/j.jhep.2026.06.025. Online ahead of print. PubMed 42402265 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Oct 2025, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2023
First posted
Mar 16, 2023
StartActual
Aug 16, 2023
Primary completionActual
Oct 2, 2025
CompletionEst.
Sep 17, 2026
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05771480
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 16, 2023
Start date
Aug 16, 2023
Primary completion
Oct 2, 2025
Completion
Sep 17, 2026 (estimated)
Last update
Jul 29, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion